JAK2 and Venous Thrombosis

Screening for JAK2V617F mutations in patients with splanchnic venous thromboses might lead to early diagnosis of myeloproliferative disorders.

The finding that JAK2V617F mutations are associated with multiple myeloproliferative disorders (MPDs), including polycythemia vera and essential thrombocythemia, has influenced approaches to early diagnosis of Philadelphia chromosome (Ph)^– myeloproliferative neoplasms (Nature 2005; 434:1144). Recent studies suggest that these mutations are commonly found in patients who have splanchnic venous thromboses (SVTs), but not in patients who have venous thromboembolism (VTE), and that many SVT patients with the mutations have no other MPD manifestations (Gastroenterology 2006; 130:2031). Should patients who present with venous thrombosis in splanchnic vessels and without overt MPDs be screened for JAK2V617F mutations?

To answer this question, inves…

Reviewing Author

David Green, MD, PhD

Disclosures

EquityNovartis

David Green, MD, PhD

Disclosures

EquityNovartis